Nkarta (NKTX) TD Cowen 45th Annual Healthcare Conference summary

Strategic focus and platform advantages

• Pivoted to autoimmune disease, leveraging allogeneic, off-the-shelf CAR-NK cells with a favorable safety profile and compatibility with rheumatology practice.

• CAR-NK approach avoids cytokine release syndrome (CRS) and ICANS, using only cyclophosphamide for lymphodepletion, which is familiar to rheumatologists.

• Membrane-bound IL-15 in the product eliminates the need for fludarabine, reducing toxicity and simplifying administration.

• CAR-NK cells can be administered in outpatient settings and redosed as needed, offering flexibility and convenience.

Clinical rationale and differentiation

• CAR-NK cells do not require prolonged persistence for efficacy in autoimmunity, focusing on rapid B cell elimination and immune reset.

• Fludarabine-free conditioning is possible due to cytokine engineering, reducing immunosuppression and toxicity.

• Cyclophosphamide provides immediate immunosuppression, aligning with the pharmacokinetics of NK cell therapy.

• Regulatory path may be clearer with cyclophosphamide-only regimens, using real-world evidence and historical controls for approval.

Early data and competitive landscape

• Prior oncology experience with NKX019 demonstrated effective B cell depletion and immune reset, supporting its use in autoimmune indications.

• CAR-NK data from China (RuiYi) in lupus showed promising remission rates and safety, comparable to CAR-T but with fewer toxicities.

• CAR-NK may offer similar efficacy to CAR-T with a better safety and administration profile, making it competitive in the space.